Volume 24, Number 4—April 2018
CME ACTIVITY - Synopsis
Reemergence of Intravenous Drug Use as Risk Factor for Candidemia, Massachusetts, USA
Table 4
Candida species isolated from blood of patients with candidemia at a tertiary care hospital, Massachusetts, USA, 2010–2017*
Organisms | No. (%) patients |
p value | |
---|---|---|---|
IVDU, n = 24 | Non-IVDU, n = 174 | ||
C. albicans | 7 (29.2)† | 93 (53.5) | 0.03 |
C. glabrata | 8 (33.3) | 39 (22.4) | 0.304 |
C. parapsilosis | 8 (33.3) | 25 (14.4) | 0.036 |
C. tropicalis | 3 (12.5) | 13 (7.5) | 0.419 |
C. dubliniensis | 0 | 2 (1.2) | 1.00 |
C. guilliermondii | 0 | 1 (0.6) | 1.00 |
C. krusei | 0 | 1 (0.6) | 1.00 |
C. lipolytica | 0 | 1 (0.6) | 1.00 |
C. kefyr | 0 | 1 (0.6) | 1.00 |
Co-infected | 2 (8.3) | 2 (1.2) | 0.073 |
*IVDU, intravenous drug use.
†Percentages do not add up to 100% because patients co-infected with 2 species are counted twice.